Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience Publisher Pubmed



Ledder O^{1, 2} ; Dolinger M³ ; Dubinsky MC³ ; Stein R⁴ ; Vellanki S⁵ ; Buckuk R¹ ; Fatima A⁶ ; Suskind DL⁷ ; Scarlett J⁷ ; Roser D⁸ ; Shouval DS^{9, 10} ; Meyer G¹¹ ; Rios ZM¹¹ ; Pujolmuncunill G¹² Show All Authors
Source: Inflammatory Bowel Diseases Published:2025

Abstract

Background: Tofacitinib has recently been approved for treatment of moderate-to-severe ulcerative colitis (UC) in adults, yet pediatric data are limited. This international multicenter study describes the effectiveness and safety of tofacitinib in pediatric UC. Methods: This is a retrospective review of children diagnosed with UC treated with tofacitinib from 16 pediatric centers internationally. The primary outcome was week 8 corticosteroid-free clinical remission (Pediatric Ulcerative Colitis Activity Index <10). Secondary outcomes were clinical response (≥20-point decrease in Pediatric Ulcerative Colitis Activity Index) at week 8, corticosteroid-free clinical remission at week 24, and colectomy rate and adverse safety events through to last follow-up. The primary outcome was calculated by the intention-to-treat principle. Results: We included 101 children with a mean age at diagnosis of 12.8 ± 2.8 years and a median disease duration of 20 months (interquartile range [IQR], 10-39 months). All had treatment failure with at least 1 biologic agent, and 36 (36%) had treatment failure with 3 agents. Median follow-up was 24 weeks (IQR, 16-54 weeks). Sixteen (16%) children achieved corticosteroid-free clinical remission at week 8, and an additional 30 (30%) demonstrated clinical response. Twenty (23%) of 88 children achieved corticosteroid-free clinical remission at week 24. A total of 25 (25%) children underwent colectomy by median 86 days (IQR, 36-130 days). No serious drug-related adverse events were reported; there was 1 case of herpes zoster and 2 cases of minor blood test perturbations. Conclusions: In this largest real-life pediatric cohort to date, tofacitinib was effective in at least 16% of patients with highly refractory UC by week 8. Adverse events were minor and largely consistent with adult data. © 2024 The Author(s). Published by Oxford University Press on behalf of Crohn's & Colitis Foundation. All rights reserved.